My focus is on of anticancer drugs. My research interests and collaborations are broad but are unified by the common thread of trying to understand causes of interpatient variability in terms of toxicity and efficacy. My major interest is understanding mechanisms of nephrotoxicity of chemotherapy especially antifolates and nucleoside analogues. My major collaborator in this research is Carol E. Cass, an international expert in nucleoside transport and therapeutics. Pharmacogenetics is another major interest that I developed during my training with M. Ratain. I am interested in the roles that polymorphisms play in the interpatient variation in drug elimination. I am also interested in the role that nutrition plays in the toxicity and efficacy of chemotherapy and have developed extensive collaborations with Drs. Vickie Baracos and Catherine Field. The research has been supported by the Alberta Cancer Board, Alberta Cancer Foundation, The Canadian Breast Cancer Foundation, The Canadian Breast Cancer Research Alliance and the Canadian Institutes of Health Research. I have received funding from Hoffman La Roche, Pfizer.